Piracetam for Health & Longevity - Quick Reference Sheet
evipedia.ai ← Back

Piracetam for Health & Longevity

Created on 07/03/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 – Audit

Piracetam, the original nootropic, is a gentle, kidney-cleared compound with a strong safety record and mild, reversible side effects. Evidence is mixed: clear value for brain-driven muscle jerks and certain childhood spells, modest inconsistent memory gains in older adults with decline, but unproven for long-term brain protection in healthy adults. (Full Review)

Protocol

Standard Dose
1,200–4,800 mg/day
Common regimen 1,600 mg three times daily (4,800 mg total)
Dosing Schedule
Split 2–3× daily
Short 4–5 h half-life; single daily dose not typical
Timing
Morning & early afternoon
Final dose kept away from bedtime to limit insomnia
Time to effect
Myoclonus
Days to a few weeks
Muscle-jerk and some cognitive endpoints
Cognitive Support
6–12 weeks
Window over which age-related cognitive outcomes are assessed
Personal Trial
At least several weeks
Minimum for a fair assessment of benefit

Benefits

Contraindications
  • Severe renal impairment (eGFR <30 mL/min); end-stage kidney disease
  • Active intracranial hemorrhage
  • Hypersensitivity to piracetam or other pyrrolidone derivatives
  • Huntington disease
  • Pregnancy and breastfeeding
    •
Key Interactions
  • Prescription anticoagulants and antiplatelet drugs (warfarin, apixaban, clopidogrel, aspirin at antiplatelet doses)
  • Over-the-counter NSAIDs (ibuprofen, naproxen) and aspirin
  • Thyroid hormone (levothyroxine, T3/T4)
  • Other cholinergic or stimulant nootropics (alpha-GPC, citicoline, caffeine, other racetams)
  • Supplements with additive antiplatelet effects (high-dose fish oil/omega-3, Ginkgo biloba, high-dose vitamin E, garlic extract)
  • CNS stimulants and amphetamine-type agents
    •

Risk & Side Effects

  • High: Central nervous system overstimulation
    •
  • Medium: Weight gain; gastrointestinal disturbance
    •
  • Low: Bleeding tendency and antiplatelet effect; headache, dizziness, and fatigue
    •
  • Speculative: Mood changes and depression; accumulation effects in impaired renal function
    •

Monitoring

Marker Target Why
eGFR >90 mL/min/1.73m² Governs drug clearance; low values cause accumulation
Serum creatinine 0.6–1.0 mg/dL Complements eGFR in tracking kidney clearance
Blood urea nitrogen (BUN) 10–16 mg/dL Secondary marker of renal clearance and hydration
Complete blood count with platelets Platelets 150–400 ×10⁹/L Screens bleeding risk given antiplatelet effect
Body weight Stable from personal baseline Detects the recognized weight-gain effect early

Cadence: Baseline kidney function and bleeding-risk screen before first dose; recheck kidney function at ~3 months, then every 6–12 months during continued use.

Qualitative Assessment

  • Cognitive clarity and memory: subjective sharpness, word-finding, and recall versus baseline
  • Sleep quality: onset, continuity, and whether later dosing disrupts sleep
  • Mood and anxiety: any increase in nervousness, irritability, or agitation
  • Energy and headache: presence of overstimulation or choline-deficiency-type headaches
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.